melodyn 35 mcg/h system transdermalny
g.l. pharma gmbh - buprenorphinum - system transdermalny - 35 mcg/h
melodyn 70 mcg/h system transdermalny
g.l. pharma gmbh - buprenorphinum - system transdermalny - 70 mcg/h
melodyn 52,5 mcg/h system transdermalny
g.l. pharma gmbh - buprenorphinum - system transdermalny - 52,5 mcg/h
oxaliplatinum accord 5 mg/ml koncentrat do sporządzania roztworu do infuzji
accord healthcare polska sp. z o.o. - oxaliplatinum - koncentrat do sporządzania roztworu do infuzji - 5 mg/ml
oxytocin panpharma 5 iu/ml koncentrat do sporządzania roztworu do infuzji
panpharma - oxytocin - koncentrat do sporządzania roztworu do infuzji - 5 iu/ml
micafungin teva 50 mg proszek do sporządzania koncentratu roztworu do infuzji
teva b.v. - micafunginum - proszek do sporządzania koncentratu roztworu do infuzji - 50 mg
micafungin teva 100 mg proszek do sporządzania koncentratu roztworu do infuzji
teva b.v. - micafunginum - proszek do sporządzania koncentratu roztworu do infuzji - 100 mg
feiba nf 500 j. (500 j. feiba) proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań
takeda pharma sp. z o.o. - białko osocza ludzkiego - proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań - 500 j. (500 j. feiba)
feiba nf 2500 j. (2500 j. feiba) proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań
takeda pharma sp. z o.o. - białko osocza ludzkiego - proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań - 2500 j. (2500 j. feiba)
blincyto
amgen europe b.v. - blinatumomab - prekursor komórkowy limfoblastyczny białaczka-chłoniak - Środki przeciwnowotworowe - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.